Multicenter, randomized, double-blinded, placebo-controlled trial of IFx-Hu2.0 (IFx) as adjunctive therapy with pembrolizumab (pembro) in checkpoint inhibitor (CPI)-naïve patients with advanced or metastatic Merkel cell carcinoma (MCC).

Authors: Andrew Scott Brohl, Melissa Amber Burgess, Gino Kim In, Karam Khaddour, Peter M O'Neill, Sunil A. Reddy, Eric D. Whitman, James A. Bianco

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps9603

Source: Full article

---

Abstract

TPS9603